Protocol Single compound
Retatrutide
GIP / GLP-1 / glucagon triple agonist
Investigational triple-hormone receptor agonist evaluated in phase 2/3 obesity trials.
Compare side by side →Compared with:Retatrutide vs TirzepatideSemaglutide vs Retatrutide
Protocol card · research reference
- Starting dose
- 2 mg
- Studied range
- 2–12 mg
- Frequency
- Once weekly
- Route
- Subcutaneous
- Cycle
- Ongoing, titrated every 4 weeks
Titration schedule
- 01Weeks 1–42 mg
- 02Weeks 5–84 mg
- 03Weeks 9–128 mg
- 04Weeks 13+12 mg (highest trial arm)
Reconstitution reference
Storage: Powder: 2–8 °C, or −20 °C for longer storage. After mixing with BAC water: 2–8 °C, use within about 4 weeks.
Retatrutide
Once weekly · units to draw on a U-100 syringe for a 2 mg dose.
| Vial | BAC water | mg/mL | Draw | Doses |
|---|---|---|---|---|
| 10 mg | 1 mL | 10 | 20 u | 5 |
| 10 mg | 2 mL | 5 | 40 u | 5 |
| 10 mg | 3 mL | 3.33 | 60 u | 5 |
| 20 mg | 1 mL | 20 | 10 u | 10 |
| 20 mg | 2 mL | 10 | 20 u | 10 |
| 20 mg | 3 mL | 6.67 | 30 u | 10 |
| 30 mg | 1 mL | 30 | 6.7 u | 15 |
| 30 mg | 2 mL | 15 | 13.3 u | 15 |
| 30 mg | 3 mL | 10 | 20 u | 15 |
Calculate your vial
Draw to
—units
= — mL on a U-100 syringe
- Concentration
- —
- Per unit
- —
- Doses / vial
- —
Research dossier · published literature summary
01
Mechanism of action
Retatrutide (LY3437943) is a single peptide agonist of three receptors: GIP, GLP-1 and glucagon. Adding glucagon-receptor activity is studied for increasing energy expenditure and liver-fat effects on top of the appetite effects of GIP/GLP-1 agonism.
02
Observed research endpoints
- Phase 2 obesity trial (338 adults): mean weight change at 48 weeks ranged from −8.7% to −24.2% across arms vs −2.1% with placebo.
- In the highest arm, 83% of participants lost 15% or more of body weight at 48 weeks, vs 2% on placebo.
- Preclinical and early clinical work describes glycaemic and weight effects from combined triple-receptor agonism.
03
Regulatory & safety context
- Investigational: not approved by the FDA or EMA for any indication. Phase 3 trials are ongoing.
- Phase 2 adverse events were mainly gastrointestinal and dose-related; heart-rate increases were also reported.
04
Citations
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526.2023-08Phase 2 randomized controlled trialRead paper ↗
- Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234–1247.2022-09Preclinical + Phase 1 studyRead paper ↗
Where researchers source it
Listings are provided for reference — always verify the latest third-party COA before purchasing.
Medvinci Research
See siteFeatured supplier · third-party tested, COA published per batch
Supplier B
TBDPlaceholder — details coming soon
Supplier C
TBDPlaceholder — details coming soon